Jazz Pharmaceuticals (JAZZ) Gets a Buy from Wells Fargo

Wells Fargo analyst Mohit Bansal maintained a Buy rating on Jazz Pharmaceuticals today and set a price target of $250.00.

Easter Sale - 70% Off TipRanks

• Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
• Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks

According to TipRanks, Bansal is a 5-star analyst with an average return of 9.2% and a 55.65% success rate. Bansal covers the Healthcare sector, focusing on stocks such as Merck & Company, Eli Lilly & Co, and Regeneron.

In a report released on April 6, RBC Capital also maintained a Buy rating on the stock with a $195.00 price target.

Based on Jazz Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $1.2 billion and a net profit of $203.45 million. In comparison, last year the company earned a revenue of $1.09 billion and had a net profit of $191.12 million

Based on the recent corporate insider activity of 83 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of JAZZ in relation to earlier this year. Last month, Patricia Carr, the SVP & CAO of JAZZ sold 2,723.00 shares for a total of $503,645.50.